New data from KYTHERA Biopharmaceuticals’ ATX-101 studies on double chin

Mar 2 2013

KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced four abstracts will be presented at the 71^st American Academy of Dermatology (AAD) Annual Meeting in Miami Beach, Fla. The abstracts, including one to be presented at the Late Breaking Research Symposium on March 2, evaluate the safety, efficacy and pharmacokinetics of ATX-101, an investigational injectable drug being studied for the nonsurgical reduction of submental fat (SMF), commonly known as the double chin. The ATX-101 global clinical development program has enrolled more than 2,500 total patients of which more than 1,500 have been treated with ATX-101.

The abstracts include:

• ATX-101 (deoxycholic acid injection) for the reduction of submental fat: Interim results from a multicenter, 12-month, open-label study (Late Breaking Research Symposium)
• ATX-101 for the reduction of double chin caused by submental fat: Results from the ATX-101-10-16 European phase III study (Poster: P6257, available March 1)
• Reduction of double chin caused by submental fat with ATX-101: Results from the ATX-101-10-17 European phase III study (Poster: P6256, available March 1)
• Open-label pharmacokinetic study to evaluate lipid levels in the blood following injections of ATX-101 (deoxycholic acid) (Poster: P5917, available March 1)

"KYTHERA Biopharmaceuticals is at the forefront of addressing the unmet need for a safe, clinically proven injectable drug for the reduction of undesirable submental fat," said Keith Leonard, president and chief executive officer, KYTHERA Biopharmaceuticals, Inc. "The data being presented this week further supports the scientific and clinical rigor of the ATX-101 development program. We look forward to the final results of our Phase III trials and potentially entering the market with this important first-in-class aesthetic drug."